Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2030 earnings at $0.67 EPS.

A number of other analysts have also recently weighed in on SGMO. Barclays reaffirmed an “equal weight” rating and issued a $1.00 price target (down previously from $5.00) on shares of Sangamo Therapeutics in a research report on Friday, November 7th. Wall Street Zen lowered Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.33.

Sangamo Therapeutics Stock Down 3.2%

SGMO stock opened at $0.38 on Tuesday. The firm has a 50 day moving average of $0.43 and a two-hundred day moving average of $0.51. Sangamo Therapeutics has a 12 month low of $0.35 and a 12 month high of $1.24. The company has a market capitalization of $127.46 million, a price-to-earnings ratio of -0.86 and a beta of 1.28.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of hedge funds have recently made changes to their positions in the business. State of Wyoming bought a new position in shares of Sangamo Therapeutics in the fourth quarter valued at approximately $47,000. Geode Capital Management LLC boosted its position in shares of Sangamo Therapeutics by 17.6% in the 4th quarter. Geode Capital Management LLC now owns 3,866,026 shares of the biopharmaceutical company’s stock worth $1,624,000 after purchasing an additional 579,550 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Sangamo Therapeutics by 328.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 150,000 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 115,000 shares during the period. R Squared Ltd grew its holdings in shares of Sangamo Therapeutics by 22.2% in the 4th quarter. R Squared Ltd now owns 147,191 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 26,732 shares during the period. Finally, Meritage Portfolio Management lifted its holdings in Sangamo Therapeutics by 28.2% during the fourth quarter. Meritage Portfolio Management now owns 227,000 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 56.92% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.